|
FBR Biotech Analyst Jim Reddoch, Ph.D., follows companies that are developing new, cutting-edge therapies for diseases such as cancer, diabetes, AIDS, and hepatitis C.
Dr. Reddoch joined FBR in May 2003, after five years of covering the biotech industry on Wall Street, most recently as a senior analyst at Banc of America Securities. He brings to FBR his methodologies for valuing biotech companies using a modified discounted cash-flow analysis.
Prior to venturing into finance, Dr. Reddoch was a postdoctoral fellow at Yale University School of Medicine, where he focused on the relationship between gene regulation and cancer. During his time at Yale, Dr. Reddoch also served as a consultant for the school�s technology transfer arm and worked on spin-outs that are now nearing the IPO stage.
He received his Ph.D. in biochemistry and molecular genetics from the University of Alabama Medical School, where he founded the Industry Roundtable now in its tenth year which features speakers in finance, law, and healthcare. Dr. Reddoch�s undergraduate degree, from Furman University, is in political science, so he feels right at home in the capital city. | 